[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1999026927A3 - Metabotropic glutamate receptor antagonists for treating central nervous system diseases - Google Patents

Metabotropic glutamate receptor antagonists for treating central nervous system diseases Download PDF

Info

Publication number
WO1999026927A3
WO1999026927A3 PCT/US1998/024833 US9824833W WO9926927A3 WO 1999026927 A3 WO1999026927 A3 WO 1999026927A3 US 9824833 W US9824833 W US 9824833W WO 9926927 A3 WO9926927 A3 WO 9926927A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabotropic glutamate
nervous system
central nervous
receptor antagonists
glutamate receptor
Prior art date
Application number
PCT/US1998/024833
Other languages
French (fr)
Other versions
WO1999026927A2 (en
Inventor
Wagenen Bradford C Van
Scott T Moe
Daryl L Smith
Susan M Sheehan
Irina Shcherbakova
Richard Travato
Ruth Walton
Robert Barmore
Eric G Delmar
Thomas M Stormann
Original Assignee
Nps Pharma Inc
Wagenen Bradford C Van
Scott T Moe
Daryl L Smith
Susan M Sheehan
Irina Shcherbakova
Richard Travato
Ruth Walton
Robert Barmore
Eric G Delmar
Thomas M Stormann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002311131A priority Critical patent/CA2311131A1/en
Application filed by Nps Pharma Inc, Wagenen Bradford C Van, Scott T Moe, Daryl L Smith, Susan M Sheehan, Irina Shcherbakova, Richard Travato, Ruth Walton, Robert Barmore, Eric G Delmar, Thomas M Stormann filed Critical Nps Pharma Inc
Priority to AU15317/99A priority patent/AU771358B2/en
Priority to JP2000522085A priority patent/JP2001524468A/en
Priority to NZ505207A priority patent/NZ505207A/en
Priority to EP98959535A priority patent/EP1037878A2/en
Priority to IL13625098A priority patent/IL136250A0/en
Priority to MXPA00004940A priority patent/MXPA00004940A/en
Publication of WO1999026927A2 publication Critical patent/WO1999026927A2/en
Publication of WO1999026927A3 publication Critical patent/WO1999026927A3/en
Priority to US09/573,347 priority patent/US6429207B1/en
Priority to IL136250A priority patent/IL136250A/en
Priority to US10/211,523 priority patent/US7053104B2/en
Priority to AU2004202776A priority patent/AU2004202776B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that act as antagonists at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.
PCT/US1998/024833 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases WO1999026927A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL13625098A IL136250A0 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonist compounds
AU15317/99A AU771358B2 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
JP2000522085A JP2001524468A (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system disorders
NZ505207A NZ505207A (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP98959535A EP1037878A2 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
CA002311131A CA2311131A1 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
MXPA00004940A MXPA00004940A (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases.
US09/573,347 US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
IL136250A IL136250A (en) 1997-11-21 2000-05-21 Metabotropic glutamate receptor antagonist compounds
US10/211,523 US7053104B2 (en) 1997-11-21 2002-08-05 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AU2004202776A AU2004202776B2 (en) 1997-11-21 2004-06-17 Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6675897P 1997-11-21 1997-11-21
US60/066,758 1997-11-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/573,347 Continuation-In-Part US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

Publications (2)

Publication Number Publication Date
WO1999026927A2 WO1999026927A2 (en) 1999-06-03
WO1999026927A3 true WO1999026927A3 (en) 1999-10-21

Family

ID=22071510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/024833 WO1999026927A2 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Country Status (9)

Country Link
EP (1) EP1037878A2 (en)
JP (1) JP2001524468A (en)
CN (2) CN1158264C (en)
AU (2) AU771358B2 (en)
CA (1) CA2311131A1 (en)
IL (2) IL136250A0 (en)
MX (1) MXPA00004940A (en)
NZ (1) NZ505207A (en)
WO (1) WO1999026927A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1059090A4 (en) * 1998-03-03 2002-02-27 Yamanouchi Pharma Co Ltd Remedies for brain infarction
GB9823845D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
CN1789246A (en) * 1999-06-02 2006-06-21 Nps药物有限公司 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1210338A2 (en) * 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1582519A3 (en) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DK1210344T3 (en) * 1999-08-19 2006-03-06 Nps Pharma Inc Heteropolycyclic Compounds and Their Uses as Metabotropic Glutamate Receptor Antagonists
RU2259360C2 (en) 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Derivatives of benzodiazepine and medicinal agent comprising thereof
DK1224175T3 (en) 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
IL155163A0 (en) 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2003027068A2 (en) * 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
CA2479109C (en) * 2002-03-29 2011-08-02 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
CN100357283C (en) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 Methionyl aminopeptidase inhibitor
RU2352568C9 (en) * 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]oxadiazoles (versions), methods of obtaining them, pharmaceutical composition and method of inhibiting activation of metabotropic glutamate receptors - 5
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CA2513824A1 (en) * 2003-01-31 2004-08-19 Astrazeneca Ab Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302192D0 (en) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7501416B2 (en) 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
US9012494B2 (en) 2004-05-07 2015-04-21 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2576839C (en) * 2004-08-30 2013-07-02 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (en) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv OXYSTEROID DEHYDROGENASE INHIBITORS
KR101197672B1 (en) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. Tricyclic Lactam Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
BRPI0611966B1 (en) 2005-06-17 2022-05-03 Apogee Biotechnology Corporation A compound or pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising them
WO2007021309A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
WO2007037543A1 (en) * 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Biarylamide derivative
WO2007045876A1 (en) * 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
EP1966144A1 (en) * 2005-12-20 2008-09-10 Novartis AG Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
KR101387563B1 (en) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 Comestible compositions comprising high potency savory flavorants, and processes for producing them
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
RU2009107688A (en) 2006-08-04 2010-09-10 Мерц Фарма Гмбх Унд Ко. Кгаа (De) Pyrazolopyrimidines, a method for their production and their use as a medicine
EP2091944B1 (en) 2006-11-17 2011-05-18 Pfizer Inc. Substituted bicyclocarboxyamide compounds
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc Methods of treating down's syndrome, fragile x syndrome and autism
ES2388454T3 (en) 2007-03-22 2012-10-15 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
WO2008128889A1 (en) 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
TWI417100B (en) 2007-06-07 2013-12-01 Astrazeneca Ab Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
CN101348461B (en) * 2007-07-17 2011-10-05 西安利君制药有限责任公司 N-(3-pyridine formyloxy)-3,5-dimethyl-1-amantadine for curing senile dementia or pharmaceutical salt thereof
EP2064959B1 (en) 2007-10-31 2012-07-25 Symrise AG Aromatic Neomenthylamides as flavouring agents
PE20091036A1 (en) 2007-11-30 2009-08-15 Astrazeneca Ab QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
SA109300358B1 (en) 2008-06-06 2012-11-03 استرازينيكا ايه بي Isoindolone Metabotropic Glutamate receptor Potentiators
US8415333B2 (en) 2009-02-24 2013-04-09 Respiratorious Ab Bronchodilating diazaheteroaryls
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012006760A1 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
AU2011335158B2 (en) * 2010-11-30 2016-09-15 Bayer Intellectual Property Gmbh Pyrimidine derivatives and use thereof as pesticides
KR102529578B1 (en) * 2014-08-29 2023-05-09 (주)아모레퍼시픽 Novel adamatan derivative compound
CN114539170B (en) * 2021-12-31 2023-05-16 华南农业大学 Hapten and artificial antigen for simultaneously detecting amantadine, olaquindox and chloramphenicol, and preparation method and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050074A1 (en) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) quinolines, their salts and derivatives, as well as processes for their preparation and their use
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2728248A1 (en) * 1976-06-24 1978-01-05 Debat Lab NITROXOLINE DERIVATIVES
EP0002066A1 (en) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited 2-Adamantyl hydrazines and pharmaceutical compositions containing them
EP0407192A2 (en) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha 4-Acyloxyquinoline derivatives and insecticidal or acaricidal compositions containing same
JPH07179371A (en) * 1993-12-21 1995-07-18 Canon Inc Liquid crystal compound, liquid crystal composition containing the compound, liquid crystal element using the composition, displaying method and displaying apparatus using the element
WO1996005818A1 (en) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
WO1996040641A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Sulfonamide derivatives as cell adhesion modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2509728A1 (en) * 1981-07-17 1983-01-21 Roussel Uclaf NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
WO1991014677A1 (en) * 1990-03-28 1991-10-03 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative, antiulcer drug containing the same, and production of said derivative
JPH0441425A (en) * 1990-06-07 1992-02-12 Tanabe Seiyaku Co Ltd 5-lipoxygenase inhibitor
JP2718830B2 (en) * 1992-07-10 1998-02-25 ラボラトワール、グラクソ、ソシエテ、アノニム Anilide derivative
EP0769015B1 (en) * 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
TR199902724T2 (en) * 1997-05-03 2000-04-21 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2050074A1 (en) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) quinolines, their salts and derivatives, as well as processes for their preparation and their use
DE2728248A1 (en) * 1976-06-24 1978-01-05 Debat Lab NITROXOLINE DERIVATIVES
EP0002066A1 (en) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited 2-Adamantyl hydrazines and pharmaceutical compositions containing them
EP0407192A2 (en) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha 4-Acyloxyquinoline derivatives and insecticidal or acaricidal compositions containing same
JPH07179371A (en) * 1993-12-21 1995-07-18 Canon Inc Liquid crystal compound, liquid crystal composition containing the compound, liquid crystal element using the composition, displaying method and displaying apparatus using the element
WO1996005818A1 (en) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
WO1996040641A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Sulfonamide derivatives as cell adhesion modulators

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 12. Bd.", 1929, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101991 *
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 9. Bd.", 1926, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101990 *
CHEMICAL ABSTRACTS, vol. 115, no. 7, 19 August 1991, Columbus, Ohio, US; abstract no. 70978a, N. S. KOZLOV ET AL.: "Synthesis of adamantane-type beta-amino ketones" page 733; XP002101994 *
F. HONG ET AL.: "Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analogue of neurotensin(8-13)", J. CHEM. SOC., PERKIN TRANS. 1, vol. 14, 1997, pages 2083 - 2088, XP002101983 *
F. SZTARICSKAI ET AL.: "Synthese und virushemmende in-vitro-Wirkung neuerer 1-substituierter Adamantanderivate", PHARMAZIE, vol. 30, no. 9, 1975, pages 571 - 581, XP002101986 *
G. FENECH ET AL.: "Derivati amidici dell'acido 1-adamantancarbossilico a potenziale attivita antivirale ed antitumorale", BOLL. CHIM. FARM., vol. 118, no. 2, 1979, pages 78 - 87, XP002101981 *
H. ZIMMER, H. D. BENSON: "Kondensierte Imidazole; Versuche zur Synthese des 13,16- und 14,16-Diazasterin-Gerüstes", CHIMIA, vol. 26, no. 3, 1972, pages 131 - 133, XP002101985 *
H.-G. BOIT: "Beilsteins Handbuch der Organischen Chemie", 1970, SPRINGER-VERLAG, BERLIN, XP002101992 *
K. H. KIM ET AL.: "Quantitative Structure-Activity Relationship in 1-Aryl-2-(alkylamino)ethanol Antimalarials", J. MED. CHEM., vol. 22, no. 4, 1979, pages 366 - 391, XP002101988 *
L. C. MARCH ET AL.: "Antimalarials. 2. Dihydro-1,3-oxazinoquinolines and Dihydro-1,3-pyridobenzoxazines", J. MED. CHEM., vol. 16, no. 4, 1973, pages 337 - 342, XP002101989 *
M. ZANISI ET AL.: "Excitatory amino acids as modulators of gonadotropin secretion", AMINO ACIDS, vol. 6, no. 1, 1994, pages 47 - 56, XP002101984 *
N. G. KOZLOV, G. P. KOROTISHOVA: "Synthesis of 1-(1-adamantyl)-2,3-dihydroxy-3-R-1-propanones", ZH. OBSHCH. KHIM., vol. 66, no. 12, 1996, pages 2039 - 2041, XP002101987 *
PATENT ABSTRACTS OF JAPAN vol. 095, no. 010 30 November 1995 (1995-11-30) *
R. LUCKENBACH: "Beilsteins Handbuch der Organischen Chemie, 3. u. 4. Eg., 22. Bd.", 1979, SPRINGER-VERLAG, BERLIN, XP002101993 *
S. S. SABRI ET AL.: "Syntheses and Antibacterial Activity of Some New N-(3-Methyl-2-quinoxalyl) Amino Alcohols and Amine 1,4-Dioxides", J. CHEM. ENG. DATA, vol. 29, no. 2, 1984, pages 229 - 231, XP002101982 *
VESTSI AKAD. NAVUK BSSR, SER. KHIM. NAVUK, no. 1, 1991, pages 60 - 65 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Also Published As

Publication number Publication date
IL136250A0 (en) 2001-05-20
WO1999026927A2 (en) 1999-06-03
AU1531799A (en) 1999-06-15
AU2004202776A2 (en) 2004-07-22
AU2004202776B2 (en) 2008-06-19
AU771358B2 (en) 2004-03-18
AU2004202776A1 (en) 2004-07-22
CN1554649A (en) 2004-12-15
IL136250A (en) 2006-12-10
CN1285820A (en) 2001-02-28
MXPA00004940A (en) 2002-10-17
EP1037878A2 (en) 2000-09-27
CA2311131A1 (en) 1999-06-03
JP2001524468A (en) 2001-12-04
CN1158264C (en) 2004-07-21
NZ505207A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
EP1679313A3 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MY131442A (en) Excitatory amino acid receptor antagonists
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
EP0686629A3 (en) Cyclohexyl tachykinine receptor antagonists
MX9704640A (en) Steroid receptor modulator compounds and methods.
WO1996019458A3 (en) Steroid receptor modulator compounds and methods
BG106762A (en) Polycycloalkylpurines as adenosine receptor antagonists
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
NO944578L (en) Excitatory amino acid receptor antagonists
FI945807A (en) 2,5-dioxo-2,5-dihydro-1H-benz / b / azepines as NMDA receptor antagonists
WO1999029308A3 (en) Method for combating obesity
WO2004048318A8 (en) Improved process for the preparation of 1,3-substituted indenes
PL335501A1 (en) Quinoxalinodiones
SI0832074T1 (en) Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136250

Country of ref document: IL

Ref document number: 98813148.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2311131

Country of ref document: CA

Ref document number: 2311131

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004940

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 522085

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 505207

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998959535

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998959535

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 178023

Country of ref document: IL